Trans-Apical Transcatheter Aortic Valve Replacement in a Dialysis Patient with Systolic Heart Failure.
Akira OshimaTeruhiko ImamuraHiroshi OnodaYohei UenoRyuichi UshijimaMitsuo SobajimaNobuyuki FukudaShigeki YokoyamaToshio DoiKazuaki FukaharaHiroshi UenoKoichiro KinugawaPublished in: Medicina (Kaunas, Lithuania) (2022)
Mortality and morbidity remain high following transcatheter aortic valve replacement (TAVR) in dialysis patients or those with low left ventricular ejection fraction. Therapeutic strategy for those with these comorbidities remains unestablished. We had a dialysis patient with peripheral artery disease and low left ventricular ejection fraction, who received successfully scheduled trans-apical TAVR following sufficient reverse remodeling by 3-month optimal medical therapy. Our strategy should be validated in a larger robust cohort.
Keyphrases
- aortic stenosis
- ejection fraction
- transcatheter aortic valve replacement
- end stage renal disease
- left ventricular
- chronic kidney disease
- heart failure
- peritoneal dialysis
- peripheral artery disease
- aortic valve
- case report
- healthcare
- cardiac resynchronization therapy
- hypertrophic cardiomyopathy
- cardiovascular disease
- type diabetes
- acute myocardial infarction
- coronary artery disease
- mitral valve
- atrial fibrillation
- mesenchymal stem cells
- acute heart failure
- cell therapy
- bone marrow
- percutaneous coronary intervention
- acute coronary syndrome
- patient reported outcomes
- patient reported